Chronic Myeloproliferative Disorders Completed Phase 1 Trials for Tipifarnib (DB04960)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00005967Tipifarnib in Treating Patients With Advanced Hematologic CancerTreatment